PUBLIC COMPANY
save$TLXTelix Pharmaceuticals Ltd
$TLXNorth Melbourne, AUupdated 3mo ago
community read0 votes
pipeline
6
marketed
1
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
1Preclinical1Phase 12Phase 21Phase 31Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…biospace · 1mo ago
- 3 steps for taking on Novartis in radiopharma: Curium up firstTo successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.biospace · 1mo ago
- Novartis secures new radioligand in $900M deal as competition strengthensAs an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a preclinical radioligand therapy from a specialist Chinese biotech.fiercebiotech · 1mo ago
- Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapiesDeals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.biospace · 2mo ago
- Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecastsDeals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.biospace · 2mo ago
- Telix and radioisotope maker ITM merge in deal worth up to $2.35BTelix Pharmaceuticals is buying German radioisotope manufacturer ITM Isotope Technologies Munich SE for $1.65 billion upfront, but some deal milestones hinge on a recently rejected drug. The merger…endpoints · 2mo ago
- Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&AAside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendoc…biospace · 2mo ago
- Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisitionTelix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera and a radiopharmaceutical supply network.fiercebiotech · 2mo ago
- STAT+: Radiopharma companies merge after one receives surprise FDA rejectionITM Isotope Technologies Munich SE and Telix Pharmaceuticals, two leading companies in the burgeoning radiopharmaceuticals field, are merging.stat · 2mo ago
- After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancerThe FDA has signed off on the first-ever glioma drug imaging diagnostic more than a year after it initially rejected the med.fiercebiotech · 2mo ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that